Entity
  • PharmNovo

    Created in 2008
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    711
  • Activities

  • Technologies

  • Entity types

  • Location

    Scheelevägen 1, 223 63 Lund, Sweden

    Lund

    Sweden

  • Employees

    Scale: 2-10

    Estimated: 10

  • Engaged corporates

    0
    0 0
  • Added in Motherbase

    3 months, 2 weeks ago
Description
  • Value proposition

    Innovation in pain relief

    PharmNovo AB is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatments. The company’s drug candidate, PN6047, effectively reduces neuropathic pain in animal models and the findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported. Furthermore, PN6047 exhibited none of the adverse events typically associated with the conventional opioids like oxycodone and morphine, such as respiratory depression, constipation, itching, or signs of abuse potential. This validates the unique preclinical profile of PN6047, which shows that it acts extremely selectively on the delta opioid receptor distinguishing it fundamentally from conventional opioids that target the mu opioid receptor.

    PN6047 is Phase II ready!



    CNS, Neurology, Chronic Pain Treatment, BioPharma, Bioscience, Chemistry, Biotechnology, Pharmacology, Proteins, DOR agonists, and Delta opioid receptor

  • Home of PN6047, a new treatment for chronic pain | PharmNovo

    Latest News from PharmNovo. Learn more about pain, neuropathic pain, chronic pain. Treatment with our lead candidate PN6047. Therapy market, our networks. There is a huge unmet medical need for people suffering from chronic pain.

  • https://www.pharmnovo.com/
Corporate interactions BETA
Corporate TypeTweets Articles
No interactions
Similar entities
Loading...
Loading...
Social network dynamics